Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BridgeBio Pharma, Inc. Director's Dealing 2025

Jan 8, 2025

30604_dirs_2025-01-08_9402e49e-9ebe-4e0f-ac89-f76b966d9755.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4/A — Form 4/A

Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2024-12-26

Reporting Person: MCCORMICK FRANK (N/A)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2024-12-26 Common Stock G 7400 Disposed 112686 Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 979979 Indirect